---
title: "Novo Nordisk beat EPS estimates by 21.8%. Its margin still slipped."
canonical_url: https://www.stockexpertai.com/journal/2026-11-15/novo-nordisk-beat-eps-estimates-by-21-8-its-margin-still-slipped-a7c6e94bd89c
last_updated: 2026-11-16T04:08:53.518Z
section: "Biotech Brief"
author: "Stock Expert AI Research"
publisher: Stock Expert AI
tickers: NVO
content_type: journal-article
---

# Novo Nordisk beat EPS estimates by 21.8%. Its margin still slipped.

## The Take
- A clear beat. Earnings per share came in at 0.89 USD against an analyst estimate of 0.731 USD.
- Thinner margin. Operating margin was 29.1%, lower than the year-ago quarter, even as revenue grew.
- Next test. The next report is due Feb. 3, 2027, with an EPS estimate of 0.68 USD.

_Novo Nordisk (NVO) topped analyst estimates in the third quarter, but its operating margin was lower than a year earlier; the reported figures do not explain why._

![NVO — Journal cover](/public-objects/streetnews/2026-11-15/BIOTECH_BRIEF-cover-515d5977.jpg)
Stock Expert AI data cover: figures from Financial Modeling Prep.
Photo credit and licence on the image

Novo Nordisk (NVO) earned more per share than analysts expected in its latest quarter, yet its operating margin was lower than a year earlier. Earnings per share were 0.89 USD against an analyst estimate of 0.731 USD. That tension, more sales but a smaller slice kept as profit, is why revenue growth and margin are worth reading together.

## The idea

When a company's sales grow, investors usually check whether profit grows with them. Sales can rise while each sale earns less, for example if costs rise faster than revenue or prices fall.

That is why investors watch two things at once: revenue growth and margin. Operating margin is the share of each sales dollar left after the costs of running the business. Growth that comes with a shrinking margin tells a different story from growth that does not.

## The example

Novo Nordisk reported on Nov. 4, 2026. Revenue was $11.90B against an analyst estimate of $11.07B, a difference of +$834.4M, or 7.5%. Earnings per share beat the estimate by +$0.16, or 21.8%.

In the third quarter ended Sept. 30, 2026, revenue was DKK 79.19B, up 5.6% from the year-ago quarter. Net income was DKK 16.74B, down 16.3% from a year earlier. Diluted EPS was 3.79 DKK, against 4.5 DKK a year earlier.

The operating margin was 29.1%, against 31.6% in the third quarter of 2025. The gross margin, which measures profit after the direct cost of making the drugs, was 77.0%, slightly higher than 76.1% a year earlier. So the squeeze showed up below the gross profit line, not in production costs.

Free cash flow, the cash left after capital spending, was DKK 28.10B in the quarter, lower than a year earlier. Separately, FMP reports net debt of DKK 90.33B as of Sept. 30, 2026.

On the product side, Reuters reported on Nov. 14, 2026 that real-world data showed patients on the Wegovy pill losing weight in their first months of use.

Our MoonshotScore for Novo Nordisk is 87, with quality its strongest section and safety its weakest.

## Risks

- **Margin pressure.** Operating margin was lower than a year earlier, and the margin trend across recent quarters has been uneven, with the first quarter of 2026 far higher than the quarters around it.
- **Competition and pricing.** In general, if competition or pricing pressure intensified, margins could fall further; the figures here do not show that this is happening.
- **Thin analyst coverage of forward numbers.** The forward EPS estimates in FMP's data rest on a single analyst each, so they are a weak guide.

## What to watch next

- **Feb. 3, 2027:** the next earnings report, 82 days after the Nov. 13 quote date. Analysts' EPS estimate is 0.68 USD and the revenue estimate is $11.78B.
- **Operating margin in that report:** whether it stays near 29.1% or moves back toward earlier levels.
- **Wegovy pill updates:** further real-world data and any company comments on uptake.

## Key facts

- Nov. 13, 2026: shares traded at 41.63 USD on the latest quote, up 2.41%, which is 35.1% below the 52-week high of 64.16 USD.
- Nov. 4, 2026: EPS of 0.89 USD against an estimate of 0.731 USD.
- Trailing 12 months: P/E of 10.91 and a dividend yield of 4.2%. For comparison, AbbVie (ABBV) has a P/E of 50.61 and AstraZeneca (AZN) has a P/E of 25.93.
- Analyst price targets: an average target of 42.33 USD, with a range from a low of 40.00 USD to a high of 47.00 USD.
- Analyst ratings: 39 ratings in total, with a consensus of Buy.

| Metric | Q3 FY2026 | Q3 FY2025 |
|---|---|---|
| Revenue | DKK 79.19B | DKK 74.98B |
| Operating margin | 29.1% | 31.6% |
| Net income | DKK 16.74B | DKK 20.01B |
| Diluted EPS | 3.79 DKK | 4.5 DKK |

## Frequently asked questions

## Q: Did Novo Nordisk beat earnings estimates in the third quarter of 2026?
Yes. Earnings per share were 0.89 USD against an analyst estimate of 0.731 USD, and revenue was $11.90B against an estimate of $11.07B, in the report dated Nov. 4, 2026.

## Q: Why did Novo Nordisk net income fall if revenue grew?
Revenue rose 5.6% from a year earlier, but net income fell 16.3%. Operating margin was 29.1%, lower than a year earlier. The figures do not by themselves give the cause.

## Q: When does Novo Nordisk report next?
The next earnings date is Feb. 3, 2027. Analysts' EPS estimate is 0.68 USD and the revenue estimate is $11.78B.


*This is educational content, not investment advice. Past performance does not guarantee future results.*

## Related Tickers
- [NVO](https://www.stockexpertai.com/stock/nvo)

## Sources
- [Stock Expert AI NVO page: quote, financials and MoonshotScore](https://www.stockexpertai.com/stock/nvo)
- [fool.com: Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027](https://www.fool.com/investing/2026/11/15/prediction-usd10-000-equally-split-between-eli-lilly-and-novo-nordisk-will-be-worth-this-much-by-the-end-of-2027/)
- [reuters.com: Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show](https://www.reuters.com/business/healthcare-pharmaceuticals/novos-wegovy-pill-helps-patients-lose-about-6-weight-three-months-real-world-2026-11-14/)
- [fool.com: Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?](https://www.fool.com/coverage/better-buy/2026/11/14/novo-nordisk-vs-pfizer-does-a-weight-loss-or-cancer-focused-pharma-stock-make-a-better-buy-for-2027/)

---
_Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article. Educational research, not financial advice._